Association Between Renal Resistive Index(RRI) and AKI(Acute Kidney Injury) in Cardiac Surgery Patients With Cardiopulmonary Bypass (CPB)
Launched by YONSEI UNIVERSITY · Jun 10, 2024
Trial Information
Current as of July 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the relationship between a test called the Renal Resistive Index (RRI) and a condition known as Acute Kidney Injury (AKI) in patients undergoing heart surgery with a technique called cardiopulmonary bypass (CPB). AKI is a common and serious complication that can occur after heart surgery and may lead to more health problems or even increased risk of death. The traditional way to check for kidney issues is through a blood test for creatinine, but this can have limitations. The RRI test, which is done using ultrasound and does not involve any invasive procedures, may help doctors identify kidney problems earlier, which could prevent AKI from becoming more severe.
To participate in this trial, individuals need to be at least 19 years old and scheduled for heart surgery that involves CPB. However, those who are in emergency situations, have severe kidney issues, or certain other health conditions may not be eligible. Participants in the trial can expect to undergo the RRI test during their treatment, which could help improve the understanding and management of kidney health in heart surgery patients. This study is not yet recruiting participants, but it aims to provide valuable insights that could lead to better outcomes for patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged 19 years and older scheduled for cardiac surgery using CPB
- Exclusion Criteria:
- • Emergency opeartion, pre-operative shock status requiring vasopressor or inotropics, s/p kidney transplant patients, CKD stage 4 and 5 patients, patients who have renal artery stenosis or history of renal artery stent implantation, patients who have ascites with Child-Pugh classification B or C, In case of CPB weaning failure, In case of poor lung function and PaO2 or PaCO2 cannot be maintained within normal range.
About Yonsei University
Yonsei University, a prestigious institution located in South Korea, is renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, Yonsei University leverages its extensive expertise and innovative approaches in various fields of medicine to conduct rigorous clinical trials aimed at improving patient outcomes and advancing healthcare solutions. The university's robust infrastructure, multidisciplinary collaboration, and adherence to ethical standards ensure the integrity and reliability of its research initiatives, making it a key player in the global clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported